PMID- 31555046
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1178-2234 (Print)
IS  - 1178-2234 (Electronic)
IS  - 1178-2234 (Linking)
VI  - 13
DP  - 2019
TI  - Bone-Targeted Agents in Breast Cancer: Do We Now Have All the Answers?
PG  - 1178223419843501
LID - 10.1177/1178223419843501 [doi]
LID - 1178223419843501
AB  - The bone-targeted agents (BTAs), bisphosphonates and denosumab, have an 
      established role in the treatment of metastatic breast cancer bone disease and 
      the prevention of cancer-treatment-induced bone loss. Evidence in support of 
      their ability to improve survival in early breast cancer now indicates that the 
      bisphosphonates are effective in postmenopausal women (naturally or chemically 
      induced), but denosumab does not have similar benefits when added to standard 
      adjuvant therapy. In postmenopausal women with early breast cancer, the choice of 
      BTA may differ depending on the indication for treatment; for fracture prevention 
      in low disease recurrence risk patients, denosumab may be favoured (in comparison 
      with placebo) to maintain bone health, and when disease recurrence prevention is 
      a priority in higher risk patients, bisphosphonates may be favoured. The reason 
      for the lack of efficacy of BTAs in premenopausal/perimenopausal patients still 
      remains unanswered and will need preclinical research to evaluate novel treatment 
      combinations with BTAs in this patient group. This review covers the past, 
      present, and future indications for BTAs in both metastatic and early breast 
      cancer.
FAU - Ottewell, Penny
AU  - Ottewell P
AD  - Department of Oncology & Metabolism, The Medical School, The University of 
      Sheffield, Sheffield, UK.
FAU - Wilson, Caroline
AU  - Wilson C
AD  - Weston Park Cancer Hospital, Sheffield Teaching Hospitals NHS Trust, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190918
PL  - United States
TA  - Breast Cancer (Auckl)
JT  - Breast cancer : basic and clinical research
JID - 101474356
PMC - PMC6751527
OTO - NOTNLM
OT  - bone-targeted agents
OT  - breast cancer
OT  - research
COIS- Declaration of conflicting interests:The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2019/09/27 06:00
MHDA- 2019/09/27 06:01
PMCR- 2019/09/18
CRDT- 2019/09/27 06:00
PHST- 2019/03/11 00:00 [received]
PHST- 2019/03/12 00:00 [accepted]
PHST- 2019/09/27 06:00 [entrez]
PHST- 2019/09/27 06:00 [pubmed]
PHST- 2019/09/27 06:01 [medline]
PHST- 2019/09/18 00:00 [pmc-release]
AID - 10.1177_1178223419843501 [pii]
AID - 10.1177/1178223419843501 [doi]
PST - epublish
SO  - Breast Cancer (Auckl). 2019 Sep 18;13:1178223419843501. doi: 
      10.1177/1178223419843501. eCollection 2019.